MedTrace Logo

E2022 Patch Formulation Single Dose Phase I Study

NCT01253434 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2013-05-14

No results posted yet for this study

Summary

The purpose of this study is to evaluate the pharmacokinetics of a single dose of E2022 in healthy Japanese male volunteers.

Conditions

  • Japanese Healthy Male Adult Volunteers

Interventions

DRUG

E2022

E2022 Type A patch

DRUG

E2022

E2022 Type B patch

DRUG

E2022

E2022 Type C patch

DRUG

E2022

E2022 Type D patch

DRUG

E2022

E2022 Type E patch

Sponsors & Collaborators

  • Eisai Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Tomoo Ogawa · Neuroscience Clinical Development Section. JAC PCU. Eisai Co., Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2011-03-31
Completion
2011-03-31

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01253434 on ClinicalTrials.gov